Blinatumomab is the first approved classical BiTE molecule, linking the variable regions of two monoclonal antibodies targeting CD19 on tumor cells and CD3 on T cells through a polypeptide chain, making blinatumomab largely Independent of genetic alterations or intracellular escape mechanisms (41). This evidence concerns the gene CD19 and neoplasm.